Torrent Pharmaceuticals Share Price Target 2026, 2027, 2030, 2040, 2050
Torrent Pharmaceuticals, started by Late Shri U. N. Mehta in Ahmedabad, Gujarat. It is a big Indian medicine company and part of the Torrent Group. It sells its medicines in more than 40 countries. The company mainly makes medicines for long-term health problems, such as heart diseases, brain and nerve issues, stomach and digestive problems, and women’s health needs. It also makes medicines for diabetes, pain, cancer, infections, and gynaecology. It is known for its strong research team, modern and high-quality factories, and smart business deals that help it grow.
What is Torrent Pharmaceuticals Ltd NSE: TORNTPHARM?
Torrent Pharmaceuticals, established in 1959 in Ahmedabad, Gujarat, and owned by the Torrent Group (led by Sudhir and Samir Mehta), is one of India’s big and well-known medicine companies. It makes many types of medicines for heart problems, brain and nerve issues, diabetes, infections, digestion, pain, cancer, and other common health needs. The company has good research teams and modern factories that help create safe and useful medicines. It sells its products all over India and in more than 50 countries, making it an important company that helps people get the medicines they need.
It works in many important medical fields. Its focus is on long-term diseases like heart problems, brain and nerve disorders, stomach and digestive issues, and women’s health. These health problems need medicines for many years, and it has strong and trusted brands in these areas. Along with this, the company also makes medicines for diabetes, cancer, infections, pain, and gynaecology. The company supports a large number of patients who need safe and effective medicines. In 2026, its share price target would be ₹5610, as per stock market analysts.
According to stock market analysts, its share price would be between ₹3650 to ₹5610 in 2026.
| वर्ष | न्यूनतम मूल्य (Rs) | अधिकतम मूल्य (Rs) |
| 2026 | 3650 | 5610 |
| महीना | न्यूनतम मूल्य (Rs) | अधिकतम मूल्य (Rs) |
| जनवरी | 3900 | 4470 |
| फ़रवरी | 3824 | 4470 |
| मार्च | 4134 | 4400 |
| अप्रैल | 3752 | 4523 |
| मई | 3650 | 4612 |
| जून | 3715 | 4874 |
| जुलाई | 4021 | 5241 |
| अगस्त | 4411 | 5310 |
| सितंबर | 4714 | 5374 |
| अक्टूबर | 5025 | 5411 |
| नवंबर | 5314 | 5532 |
| दिसम्बर | 5385 | 5610 |
It focuses on specific therapy areas instead of making every type of medicine. This approach is called niche marketing. The company chooses a few important medical areas and tries to become a leader in them. This helps the company to understand what doctors and patients really need. It also helps the company invest more in research and build stronger brands. This strategy has made it a top player in heart care, brain care, digestion, and women’s health in India and in several other countries. In 2027, its share price target would be ₹6322, as per stock market analysts.
According to stock market analysts, its share price would be between ₹5257 to ₹6322 in 2027.
| वर्ष | न्यूनतम मूल्य (Rs) | अधिकतम मूल्य (Rs) |
| 2027 | 5257 | 6322 |
It has a strong business network across India. It works with thousands of distributors, dealers, and medical stores. The company has many sales teams that meet doctors, clinics, and hospitals in both big cities and small towns. Its medicines are easily available, making it simple for patients to buy what they need. The company also teaches healthcare professionals about its medicines to ensure they are used safely. This wide network has helped Torrent become one of the most trusted pharma companies in India. In 2028, its share price target would be ₹7228, as per stock market analysts.
According to stock market analysts, its share price would be between ₹6184 to ₹7228 in 2028.
| वर्ष | न्यूनतम मूल्य (Rs) | अधिकतम मूल्य (Rs) |
| 2028 | 6184 | 7228 |
It has many modern and advanced manufacturing plants in India. These plants use high-quality machines, strict safety rules, and careful testing methods to make sure every medicine is safe and effective. Some plants produce tablets and capsules, while others make the raw materials needed for medicines. All facilities follow strict global rules, which allow them to supply medicines to regulated countries like the US and Europe. In 2029, its share price target would be ₹8115, as per stock market analysts.
According to stock market analysts, its share price would be between ₹7100 to ₹8115 in 2029.
| वर्ष | न्यूनतम मूल्य (Rs) | अधिकतम मूल्य (Rs) |
| 2029 | 7100 | 8115 |
It spends a lot of money on research and development (R&D) to make better medicines. Its R&D teams work on developing new drug formulas, improving existing products, and ensuring safety. The company uses modern labs and advanced technology to stay competitive. It launches new medicines in its main therapy areas and also enters new disease segments with the help of its R&D team. In 2030, its share price target would be ₹8984, as per stock market analysts.
According to stock market analysts, its share price would be between ₹8005 to ₹8984 in 2030.
| वर्ष | न्यूनतम मूल्य (Rs) | अधिकतम मूल्य (Rs) |
| 2030 | 8005 | 8984 |
| महीना | न्यूनतम मूल्य (Rs) | अधिकतम मूल्य (Rs) |
| जनवरी | 8005 | 8357 |
| फ़रवरी | 8042 | 8390 |
| मार्च | 8068 | 8475 |
| अप्रैल | 8120 | 8565 |
| मई | 8178 | 8590 |
| जून | 8225 | 8615 |
| जुलाई | 8365 | 8678 |
| अगस्त | 8410 | 8735 |
| सितंबर | 8452 | 8775 |
| अक्टूबर | 8479 | 8810 |
| नवंबर | 8552 | 8855 |
| दिसम्बर | 8615 | 8984 |
Today, it is among India’s top pharma companies. Its strong focus on long-term diseases like heart, nerve, and digestive problems has made it a trusted name among doctors and patients. The company stands out because of its high-quality medicines, wide distribution network, and steady performance. It has built a strong reputation for reliability and patient care. This position helps it compete well with both Indian and international pharmaceutical brands. In 2040, its share price target would be ₹15321, as per stock market analysts.
According to stock market analysts, its share price would be between ₹13658 to ₹15321 in 2040.
| वर्ष | न्यूनतम मूल्य (Rs) | अधिकतम मूल्य (Rs) |
| 2040 | 13658 | 15321 |
| महीना | न्यूनतम मूल्य (Rs) | अधिकतम मूल्य (Rs) |
| जनवरी | 13658 | 13931 |
| फ़रवरी | 13721 | 14125 |
| मार्च | 13812 | 14221 |
| अप्रैल | 13885 | 14335 |
| मई | 13985 | 14398 |
| जून | 14110 | 14458 |
| जुलाई | 14158 | 14568 |
| अगस्त | 14235 | 14687 |
| सितंबर | 14284 | 14785 |
| अक्टूबर | 14458 | 14968 |
| नवंबर | 14658 | 15125 |
| दिसम्बर | 14874 | 15321 |
It aims to become one of the most respected global pharma companies. Its mission is to provide safe, high-quality, and effective medicines that improve people’s lives. The company plans to grow by increasing its research work, expanding into global markets, and building new manufacturing facilities. It also wants to enter more medical areas and offer advanced healthcare solutions. With a strong focus on innovation, quality, and patient well-being, the company hopes to help even more people live healthier lives in the future. In 2050, its share price target would be ₹20216, as per stock market analysts.
According to stock market analysts, its share price would be between ₹19153 to ₹20216 in 2050.
| वर्ष | न्यूनतम मूल्य (Rs) | अधिकतम मूल्य (Rs) |
| 2050 | 19153 | 20216 |
| महीना | न्यूनतम मूल्य (Rs) | अधिकतम मूल्य (Rs) |
| जनवरी | 19153 | 19421 |
| फ़रवरी | 19254 | 19587 |
| मार्च | 19358 | 19688 |
| अप्रैल | 19458 | 19758 |
| मई | 19568 | 19856 |
| जून | 19689 | 19935 |
| जुलाई | 19874 | 20125 |
| अगस्त | 19921 | 20255 |
| सितंबर | 20020 | 20358 |
| अक्टूबर | 20090 | 20474 |
| नवंबर | 21120 | 20568 |
| दिसम्बर | 21251 | 20689 |
Should I buy Torrent Pharmaceuticals stock?
| वर्ष | न्यूनतम मूल्य (Rs) | अधिकतम मूल्य (Rs) |
| 2026 | 3650 | 5610 |
| 2027 | 5257 | 6322 |
| 2028 | 6184 | 7228 |
| 2029 | 7100 | 8115 |
| 2030 | 8005 | 8984 |
| 2040 | 13658 | 15321 |
| 2050 | 19153 | 20216 |
This stock can be a good choice for long-term investment. The company is strong because it makes important medicines for long-term health problems, has good research teams, sells products in many countries, and has steady demand. This helps the company grow over time. It has also bought other companies to get bigger. If you want stable growth and can handle some risk, it might be suitable, but you should check your finances and understand the risks before buying.
Torrent Pharmaceuticals earnings results
| मार्च 2020 | मार्च 2021 | मार्च 2022 | मार्च 2023 | मार्च 2024 | मार्च 2025 | टीटीएम | |
| बिक्री + | 7,939 | 8,005 | 8,508 | 9,620 | 10,728 | 11,516 | 12,248 |
| व्यय + | 5,769 | 5,524 | 6,077 | 6,778 | 7,360 | 7,795 | 8,255 |
| परिचालन लाभ | 2,170 | 2,480 | 2,431 | 2,842 | 3,368 | 3,721 | 3,993 |
| OPM % | 27% | 31% | 29% | 30% | 31% | 32% | 33% |
| अन्य आय + | 121 | 57 | -288 | 45 | 146 | -1 | -86 |
| ब्याज | 451 | 353 | 255 | 333 | 354 | 252 | 217 |
| व्याख्या | 654 | 658 | 662 | 707 | 808 | 795 | 805 |
| कर से पहले लाभ | 1,187 | 1,526 | 1,226 | 1,847 | 2,352 | 2,673 | 2,885 |
| कर | 14% | 18% | 37% | 33% | 30% | 28% | |
| नेट प्रॉफिट + | 1,025 | 1,252 | 777 | 1,245 | 1,656 | 1,911 | 2,140 |
| रुपये में ईपीएस | 30.28 | 36.99 | 22.97 | 36.79 | 48.94 | 56.47 | 63.22 |
| लाभांश भुगतान % | 53% | 47% | 105% | 60% | 57% | 57% |
कुंजी मीट्रिक
| TTM PE Ratio | PB अनुपात | लाभांश प्राप्ति | सेक्टर PE | सेक्टर PB | सेक्टर Div Yld |
| 59.40 | 16.75 | 0.85% | 37.17 | 5.87 | 0.58% |
Peers & तुलना
| स्टॉक | पीई अनुपात | PB अनुपात | लाभांश प्राप्ति |
| Torrent Pharmaceuticals Ltd | 66.51 | 16.75 | 0.85% |
| Sun Pharmaceutical Industries Ltd | 39.62 | 5.97 | 0.89% |
| Cipla Ltd | 23.35 | 3.93 | 1.05% |
| डॉ रेड्डी की लेबोरेटरीज़ लिमिटेड | 18.37 | 3.06 | 0.64% |
Is Torrent Pharmaceuticals stock good to buy? (bull case & bear case)
बुल केस:
- Its revenue grew to ₹3,178 crore in Q1 FY26 from ₹2,790 crore last year, showing it is making more money.
- Net profit increased about 30% year-on-year in Q2 FY26 to ₹537 crore, demonstrating strong earnings.
- The company focuses on long-term medicines for the heart, digestion, brain, and women’s health, which people need regularly.
- Buying other companies, like JB Chemicals, can help Torrent sell more products and reach more markets.
- Strong research teams and modern factories allow Torrent to make new medicines and maintain high quality.
भालू का मामला:
- The stock price is already high, which may limit short-term gains.
- Joining new companies, like JB Chemicals, may have problems and reduce profits.
- Changes in government rules, more competition, or currency issues could lower earnings.
निष्कर्ष
It is a top medicine company in India. It makes medicines for the heart, brain, digestion, women’s health, and other long-term health problems. The company has strong research teams, modern factories, and sells its products in over 50 countries, which has made it trusted by many people. Experts expect the company to grow steadily with new medicines and by buying other companies. The stock is a bit expensive and faces competition and government rules, but its steady earnings and focus on long-term medicines make it a good choice for investors who can take some risk.
